Revenue - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021 USD ($) dose	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) dose	Sep. 30, 2020 USD ($)	Aug. 31, 2021 dose	May 31, 2021 dose	Dec. 31, 2020 USD ($)
Revenue Recognition
Revenues	$ 178,844	$ 157,024	$ 924,090	$ 195,939
Deferred revenue, current	1,262,360		1,262,360				$ 273,228
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue Recognition
Amount of transaction price not yet satisfied	$ 7,200,000		$ 7,200,000
Remaining performance obligation, expected timing of satisfaction, period	12 months		12 months
Royalties
Revenue Recognition
Revenues	$ 39,941	$ 0	$ 63,398	$ 0
OWS Agreement
Revenue Recognition
Increase (decrease) in contract ceiling	52,900		52,900
Revised contract ceiling amount	1,800,000		$ 1,800,000
Funding	$ 1,750,000
Number of doses of the vaccine | dose	100,000,000		100,000,000
SK Bioscience Agreement
Revenue Recognition
Number of doses of the vaccine | dose	40,000,000		40,000,000
Takeda Pharmaceutical Company Limited
Revenue Recognition
Number of doses of the vaccine | dose	150,000,000		150,000,000
Advance Purchase Agreements - Canada
Revenue Recognition
Number of doses of the vaccine | dose	52,000,000		52,000,000
Additional purchase option | dose	24,000,000		24,000,000
Deferred revenue, current	$ 1,200,000		$ 1,200,000
Gavi Advance Purchase Agreement- SIIPL
Revenue Recognition
Number of doses of the vaccine | dose						1,100,000,000
Upfront payment	350,000		350,000
Additional payment after emergency use listing	$ 350,000		$ 350,000
Gavi Advance Purchase Agreement - COVAX Facility
Revenue Recognition
Number of doses of the vaccine | dose						350,000,000
European Commissions ("EC")
Revenue Recognition
Number of doses of the vaccine | dose					100,000,000
European Commissions ("EC") | Minimum
Revenue Recognition
Number of doses of the vaccine | dose					20,000,000